- Home
- HRMY vs ADEA Comparison
HRMY vs ADEA Comparison
Compare HRMY & ADEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- ADEA
- Stock Information
- Founded
- HRMY 2017
- ADEA 1990
- Country
- HRMY United States
- ADEA United States
- Employees
- HRMY N/A
- ADEA N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- ADEA Computer Software: Prepackaged Software
- Sector
- HRMY Health Care
- ADEA Technology
- Exchange
- HRMY Nasdaq
- ADEA Nasdaq
- Market Cap
- HRMY 1.9B
- ADEA 1.8B
- IPO Year
- HRMY 2020
- ADEA N/A
- Fundamental
- Price
- HRMY $26.87
- ADEA $17.26
- Analyst Decision
- HRMY Strong Buy
- ADEA Strong Buy
- Analyst Count
- HRMY 10
- ADEA 4
- Target Price
- HRMY $51.30
- ADEA $19.50
- AVG Volume (30 Days)
- HRMY 1.0M
- ADEA 568.5K
- Earning Date
- HRMY 10-28-2025
- ADEA 11-06-2025
- Dividend Yield
- HRMY N/A
- ADEA 1.16%
- EPS Growth
- HRMY 58.41
- ADEA 80.44
- EPS
- HRMY 3.10
- ADEA 0.74
- Revenue
- HRMY $772,527,000.00
- ADEA $378,674,000.00
- Revenue This Year
- HRMY $19.94
- ADEA $9.49
- Revenue Next Year
- HRMY $16.65
- ADEA $4.94
- P/E Ratio
- HRMY $8.72
- ADEA $23.23
- Revenue Growth
- HRMY 17.74
- ADEA 5.47
- 52 Week Low
- HRMY $26.26
- ADEA $10.59
- 52 Week High
- HRMY $41.61
- ADEA $18.25
- Technical
- Relative Strength Index (RSI)
- HRMY 27.45
- ADEA 64.00
- Support Level
- HRMY $26.56
- ADEA $16.36
- Resistance Level
- HRMY $27.48
- ADEA $16.98
- Average True Range (ATR)
- HRMY 1.01
- ADEA 0.58
- MACD
- HRMY -0.25
- ADEA 0.04
- Stochastic Oscillator
- HRMY 8.99
- ADEA 62.98
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.